Market Overview

Eagle Pharmaceuticals: Q3 Earnings Insights



Shares of Eagle Pharmaceuticals (NASDAQ:EGRX) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 350.00% over the past year to $1.17, which beat the estimate of $0.28.

Revenue of $49,928,000 rose by 21.34% from the same period last year, which beat the estimate of $47,020,000.


Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

Details Of The Call

Date: Nov 02, 2020

Time: 08:30 AM

ET Webcast URL:


Company's 52-week high was at $64.94

52-week low: $33.80

Price action over last quarter: Up 7.88%

Company Overview

Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development, and under review for approval by the Food and Drug Administration.


Related Articles (EGRX)

View Comments and Join the Discussion!

Posted-In: Earnings News